The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Abstract
BACKGROUND: No safe and convenient regimen has proved to be effective for the management of recurrent vulvovaginal candidiasis. METHODS: After inducing clinical remission with open-label fluconazole given in three 150-mg doses at 72-hour intervals, we randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluconazole (150 mg) or placebo weekly for six months, followed by six months of observation without therapy. The primary outcome measure was the proportion of women in clinical remission at the end of the first six-month period. Secondary efficacy measures were the clinical outcome at 12 months, vaginal mycologic status, and time to recurrence on the basis of Kaplan-Meier analysis. RESULTS: Weekly treatment with fluconazole was effective in preventing symptomatic vulvovaginal candidiasis. The proportions of women who remained disease-free at 6, 9, and 12 months in the fluconazole group were 90.8 percent, 73.2 percent, and 42.9 percent, as compared with 35.9 percent, 27.8 percent, and 21.9 percent, respectively, in the placebo group (P< 0.001). The median time to clinical recurrence in the fluconazole group was 10.2 months, as compared with 4.0 months in the placebo group (P<0.001). There was no evidence of fluconazole resistance in isolates of Candida albicans or of superinfection with C. glabrata. Fluconazole was discontinued in one patient because of headache. CONCLUSIONS: Long-term weekly treatment with fluconazole can reduce the rate of recurrence of symptomatic vulvovaginal candidiasis. However, a long-term cure remains difficult to achieve.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although symptom resolution is achieved in ~90% of women with RVVC who undergo ⩾6 months of maintenance therapy,16,21,22 up to 50% will have a recurrence after the termination of maintenance therapy. 13”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [21]
In the citing paper
“A landmark RVVC treatment study using an induction regimen of fluconazole (three 150 mg doses at 72 h intervals) followed by weekly maintenance doses of 150 mg of fluconazole for 6 months was shown to reduce symptoms and recurrences. 21”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [21]
In the citing paper
“The mainstay of treatment for most cases of uncomplicated VVC is azole antifungals, which, by inhibiting the fungal enzyme CYP51, prevent the accumulation of fungitoxic sterols [11,34].”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [34]
In the citing paper
“During the treatment phases, relapse rates vary between 21% (Donders et al., 2008a), 57.1% (Sobel et al., 2004), and 71.9% (Bolouri et al., 2009) at 12 months depending upon the characteristics of the therapeutic regimen used, as described in Supplementary Tables 2 and 3 .”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“Likewise, other studies found that up to 50% of women with RVVC relapsed after stopping their maintenance therapy regimen (Sobel et al., 2004; Donders et al., 2008a) or that additional fluconazole therapy was continued for longer than 6 months due to either culture-confirmed VVC recurrence, microbiologically unconfirmed but clinically possible VVC recurrence, or due to patients’ preference to”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“With the regimen proposed by Sobel et al. (Sobel et al., 2004) (150 mg of oral fluconazole or placebo once a week for 6 months, after a successful induction phase), 42.9% of 387 women were still disease free at 12 months, indicating over half relapsed after maintenance therapy with fluconazole was stopped.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“Median time to clinical and mycological relapse was 10.2 and 8.4 months, respectively.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“With the regimen proposed by Sobel et al. (Sobel et al., 2004) (150 mg of oral fluconazole or placebo once a week for 6 months, after a successful induction phase), 42.9% of 387 women were still disease free at 12 months, indicating over half relapsed after maintenance therapy with fluconazole was stopped.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“Although oral fluconazole is highly effective at reducing acute episodes during maintenance therapy, long-term remission after stopping the regimen is only present in about half of patients (Sobel et al., 2004; Donders et al., 2008a).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
Citations
Cites
Hepatic Injury Associated With Ketoconazole Therapy
Lewis, J. H., Zimmerman, H. J., Benson, G. D., & Ishak, K. G. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80021-9 · Cited by 392
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis
Sobel, J. D. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(85)80003-x · Cited by 332
Self-citationImmunopathogenesis of recurrent vulvovaginal candidiasis
Fidel, P. L., & Sobel, J. D. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.3.335 · Cited by 298
Self-citationRecurrent Vulvovaginal Candidiasis
Sobel, J. D. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612043152305 · Cited by 219
Self-citationCandida vaginitis: Self-Reported Incidence and Associated Costs
Foxman, B., Barlow, R., Dʼarcy, H., Gillespie, B., & Sobel, J. D. (2000) · Sexually Transmitted Diseases · doi:10.1097/00007435-200004000-00009 · Cited by 158
Self-citationWeekly Fluconazole for the Prevention of Mucosal Candidiasis in Women with HIV Infection
Schuman, P. C., Capps, L., Peng, G., Vazquez, J., El-Sadr, W. M., Goldman, A. I., Alston, B., Besch, C. L., Vaughn, A., Thompson, M., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-9-199705010-00003 · Cited by 120
Self-citationFoxman, B., MARSH, J. V., Gillespie, B. W., & Sobel, J. D. (1998) · Journal of Women s Health · doi:10.1089/jwh.1998.7.1167 · Cited by 92
Self-citationHouang, E. T., Chappatte, O., Byrne, D., Macrae, P. V., & Thorpe, J. E. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.5.909 · Cited by 76
Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis
Spinillo, A., Pizzoli, G., Colonna, L., Nicola, S., Seta, F. D., & Guaschino, S. (1994) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(94)90096-5 · Cited by 72
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis.
Sobel, J. D. (1985) · PubMed · Cited by 62
Self-citation
Cited by
Sorted by citations
Items 401–489 of 489
Infektionen in Gynäkologie und Geburtshilfe
Witt, A., & Kiss, H. (2009) · Der Gynäkologe · doi:10.1007/s00129-008-2231-8
Suspicion d'infection génitale basse
Linet, T., & Nizard, J. (2010) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(09)45139-1
Treatment of persistent thrush
Hamzah, L. (2012) · Independent Nurse · doi:10.12968/indn.2012.3.9.93721
Rosenfeld, J. A. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511642111.010
Cellular Immunity in Women with Recurrent Genital Candidosis
Suzana, T., Miladinović-Tasić, N., Stanković-Đorđević, D., & Vlahović, P. (2008) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2008.10817514
Олеговна, М. И., Natalia, Y., Yuri, V., & Vladimir, S. (2014) · Сибирский медицинский журнал (Иркутск)
Not That Itch Again: Dealing With Recurrent Vulvovaginal Candidiasis
Watson, C. J. (2008) · Nursing for Women s Health · doi:10.1111/j.1751-486x.2008.00326.x
Antifungal Susceptibility Testing and Therapy
Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2009) · Springer eBooks · doi:10.1007/978-3-642-03150-2_14
Vulval Complaints in Postmenopausal Women
Sk, G., & MacLean, A. (2008) · Aging Health · doi:10.2217/1745509x.4.5.543
Characterization and eradication of persisters in Candida albicans biofilms
Fleur, L., & David, M. Z. (2008)
Female Genital Pain and Penetration Disorders
Lev‐Sagie, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-22150-2_4
L'ImpIego deL fLuconazoLo neLLa teRapIa deLLe vuL vo-vagInItI da candIda: up-to-date
Guida, G., & Aloysio, D. D. (2008)
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Wendel, G. D. (2006) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/s1090-798x(08)70490-9
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Stockman, J. A. (2006) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(07)70127-6
Krapf, J. M. (2014) · Postgraduate Obstetrics & Gynecology · doi:10.1097/01.pgo.0000455269.18554.e8
Recurrent Vulvovaginal Candidiasis: Suppression by Fluconazole
Blacklow, N. R. (2004) · Journal watch · doi:10.1056/id200409100000001
Treating Recurrent Vulvovaginal Candidiasis
Kaunitz, A. M. (2004) · Journal watch · doi:10.1056/wh200410190000002
Aus der Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe der
München, L.-M.-U. (2015)
Infektionen an Vulva, Vagina und Zervix
Friese, K. (2009)
Candidiasis, I. (2012) · CyberLeninK (CyberLeninka)
Hirekatur, R. S. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2954-0.50029-6
OLSEN, M. E., & Rizk, B. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316084380.015
Spectrum of Activity, Pharmacology, and Clinical Indications
Nett, J. E., & Andes, D. R. (2015)
Choroby przenoszone drogą płciową – zagrożenie na wakacjach
Choroszy-Król, I. (2011) · Family Medicine & Primary Care Review
Diagnosis and Treatment of Vulvovaginitis
Zapata, M. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-17002-2_25-1
Weekly Fluconazole Prevents Recurrent Candida Vaginitis
Brett, A. S. (2004) · Journal watch · doi:10.1056/jw200409030000003
Burdette, L. (2018) · Physician Assistant Clinics · doi:10.1016/j.cpha.2018.02.009
Infecciones candidiásicas recidivantes
Hirekatur, R. S. (2009) · Elsevier eBooks · doi:10.1016/b978-84-458-1911-1.50025-7
Hellgren, G., & Parent, D. (2019) · Revue Medicale de Bruxelles · doi:10.30637/2019.18-019
Rezidivierende urogynäkologische Infektionen
Betschart, C., Dedes, I., & Scheiner, D. (2020) · Praxis · doi:10.1024/1661-8157/a003368
Prevalence of Candidiasis amongst Undergraduate Students of COOU, Uli, Nigeria
Nkiru, U. C., Ukoha, C. C., Ezechi, E. T., Njideka, O. C., Ifeoma, E. H., Ifeynwa, I. M., Oluchukwu, C. E., & Chibueze, O. U. (2020) · Global Journal of Medical Research · doi:10.34257/gjmrcvol20is1pg1
Kakar, S., & Mindel, A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-4064-1.00056-7
Nanostructure Drug Delivery System: An Inimitable Approach for Candidiasis Therapy
Sharma, R., Sharma, S., & Rana, V. (2020) · Springer eBooks · doi:10.1007/978-3-030-41858-8_15
Fredericks, L. R., Lee, M. D., Eckert, H. R., Li, S., Shipley, M. A., Roslund, C. R., Boikov, D. A., Kizer, E. A., Sobel, J. D., & Rowley, P. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.14.339788
Self-citationBest Practice & Research Clinical Obstetrics and Gynaecology
Hay, P., & Ugwumadu, A. H. N. (2009)
Рафиковна, Р. М., & Tarasenko, E. N. (2021) · Russian Journal of Clinical Dermatology and Venereology · doi:10.17116/klinderma2021200217
Vulvo-vaginite candidosique récidivante
Ly, S. (2021) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/j.fander.2021.05.002
Dermatoses infectieuses non sexuellement transmissibles
Dauendorffer, J. ‐., & Ly, S. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-76828-6.00005-6
Hochedez, P., Datry, A., & Caumes, É. (2008) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(08)70379-6
Richardson, M. D., & Warnock, F. D. W. (2012) · Wiley eBooks · doi:10.1002/9781118321492.ch5
Kauffman, C. A., & Hedderwick, S. A. (2006) · Infectious disease and therapy · doi:10.3109/9780203909447.026
Hof, H. (2020) · Der Gynäkologe · doi:10.1007/s00129-020-04664-6
Diseases of the Female Genitalia
Karrer, S. (2009) · Springer eBooks · doi:10.1007/978-3-540-29316-3_74
Recurrent Candidosis in Clinical Practice of Obstetrician- Gynecologist
Бурьяк, Д. В. (2020) · Репродуктивное здоровье Восточная Европа · doi:10.34883/pi.2020.10.4.003
Interventions to improve vaginal health for reducing the risk of HIV acquisition
Nwagbara, B. A., Effa, E., Danladi, A., & Osagie, O. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009869
RetractedHirekatur, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1793-8.00021-2
Entz�ndliche Erkrankungen der Vulva und Vagina
Gingelmaier, A., & Friese, K. (2005) · Der Gynäkologe · doi:10.1007/s00129-004-1647-z
Sobel, J. D. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.11.1025
Self-citationFischer, G. O., Bradford, J. A., & Margesson, L. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316535844.009
Moyal‐Barracco, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-33142-3_43
Fluconazol en lactobacillen bij vaginale candida
(2004) · Huisarts en Wetenschap · doi:10.1007/bf03083681
Conageski, C. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316084380.023
Diagnosis and Treatment of Vulvovaginitis
Zapata, M. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-17798-4_25
Lacroix, C., & de Chauvin, M. F. (2009) · EMC - Dermatología · doi:10.1016/s1761-2896(09)70349-8
Candida Vajinitinin Tedavisinde Otesekonazol (VT-1161): Güncel Durum
Karakoyun, A. S., Sucu, M., & İlkit, M. (2022) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.54453/tmcd.2022.36024
Criscuolo, A. A., Patrizi, L., Cannizzaro, M. V., Schipani, C., Piccolo, A., Pensa, C., Cappelli, C., Ciotti, M., Duca, E. D., Bianchi, L., et al. (2022) · Italian Journal of Gynaecology and Obstetrics · doi:10.36129/jog.2022.51
Bacterial vaginosis: diagnosis and management
(2023) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2023.1.188606
Rakhmatulina, M. R. (2023) · Vestnik dermatologii i venerologii · doi:10.25208/vdv11879
Jaber, H. H., Hussain, A. H. A., Al-Garawi, N. A.-H. D., & Muhsien, A. M. (2023) · AIP conference proceedings · doi:10.1063/5.0181990
RetractedManagement of Candida albicans infections by lactic acid bacteria
Vikrant, V., Sharma, A., Priyanka, P., & Azmi, W. (2023) · Annals of Phytomedicine An International Journal · doi:10.54085/ap.2023.12.2.8
CLINICAL MANAGEMENT OF RECURRENT CANDIDIASIS: WHAT DOES THE EVIDENCE SAY?
Bezerra, P. V. S., Neto, G. C. D. A. M., pimentel, C. F., Betmann-Azevêdo, K., Lins, J. R. D. V., Silva, B. O. G. E., Amorim, P. H. B. D. M., Correia, M. M. G., Patriota, M. C. A. M., Santos, M. P. D. M., et al. (2024) · International Journal of Health Science · doi:10.22533/at.ed.15944724290510
Reehana, N., Imran, M. M., Thajuddin, N., & Dharumadurai, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22348-8.00013-1
Wilson, J. (2025) · Sexually Transmitted Infections · doi:10.1136/sextrans-2025-056532
Greenberg, R. G., Fisher, B. T., & Otto, W. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00217-x
Martens, M. G., Wright, H., & Thorton, J. (2025) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2025.155071
Self-citationCho, H., Kim, M.-K., Choe, Y.-S., Son, S.-Y., Kang, C.-G., Lim, S.-J., Kim, S., Choi, H., Jung, U. S., & Kang, J. (2025) · Biomedicines · doi:10.3390/biomedicines13123076
Chelmow, D. P., Isaacs, C. R., & Carroll, A. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107281936.002
LInhares, I., Haddad, J. M., Fukazawa, E. I., & Baracat, E. C. (2020) · doi:10.5680/lhuii000053
Recurrent Vulvovaginal Candidosis and its Underlying Mechanisms: A Systematic Review
Lobo, M. J. F. M. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/rq9c-tj88
Jadhav, S. V., Bhalerao, A., & Ansari, Z. N. (2026) · Medical Mycology · doi:10.1093/mmy/myag048
Management of Infectious Diseases and the Pharmacist’s Role: Fungal Infections
Khan, R. A., Ramadas, A., Makhtar, S. N. A., Osman, M., & Woh-Yon, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00050-4
Difficult-to-Treat Vaginal Infections: Current Best Practices
Harbison, H. S., & Stephens, R. (2026) · Clinical Journal for Nurse Practitioners in Women s Health · doi:10.1891/cjnpwh-2025-0060
Kurahatti, R. A., Chaithra, K., & Sagar, S. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.70s.190
Nurat, A. A., Idowu, P., & Adekola, S. A. (2026) · Research Square · doi:10.21203/rs.3.rs-10412011/v1
Kurahatti, R. A., Chaithra, K., & Sagar, S. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.71s.121
Candida Infections: Epidemiology, Clinical Manifestations and Quality-of-Life Burden
Miljković, A. R. (2026) · Microbiology Research · doi:10.3390/microbiolres17080154
Mai, H. T., Nguyen, C. C., Nguyen, T. T. B., Vo, H. T. N., Pham, T. T., Nguyen, N. T. B., Nguyen, N. T. B., Doan, H., Vu, H. T., Nguyen, M. D., et al. (2026) · Beneficial Microbes · doi:10.1163/18762891-bja00131
Mihalik, N., Szulágyi-Kovács, A., Pesthy, L., Keresztes, D., & Szlávicz, E. (2026) · Bőrgyógyászati és Venerológiai Szemle · doi:10.7188/bvsz.2026.102.1.7
Recurrent Vulvovaginal Candidiasis: Risk, Prevention and QoL (2020–2026)
Novak, S. M., Kocić, B., Nikolić, M. D., Milenković, N., Popović, N. M., & Rancic, N. K. (2026) · Microbiology Research · doi:10.3390/microbiolres17090170
Plata, J. D., Rizo, D. L. V., Gonzalez, P., & Peman, J. (2026) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000986
Management of Recurrent Vaginitis
Yazdy, G. M., Powell, A. M., & Tuddenham, S. (2026) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2026.08.010
Hashmi, S. Z. A., Meena, M., & Pandit, A. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.71s.149
Metadata
- Authors
- Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., Edwards, L., Panzer, H., & Chu, T.-C.
- Affiliations
- Wayne State University (US)
- University of Pittsburgh (US)
- Hennepin County Medical Center (US)
- University of Washington (US)
- Johns Hopkins University (US)
- Pfizer (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-08-26
- Volume
- 351
- Issue
- 9
- Pages
- 876-883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2106311471
- Cited by
- 487
- References
- 21
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 17 · 2023: 26 · 2022: 22 · 2021: 21 · 2020: 22 · 2019: 15 · 2018: 28 · 2017: 30 · 2016: 26 · 2015: 29 · 2014: 23 · 2013: 24 · 2012: 23
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Keywords
- recurrent vulvovaginal candidiasis, fluconazole, maintenance therapy, Candida albicans, Candida glabrata, antifungal resistance, superinfection, recurrence prevention, clinical remission
- MeSH terms
- Administration, Oral, Adult, Antifungal Agents, Candida albicans, Candidiasis, Vulvovaginal, Double-Blind Method, Drug Administration Schedule, Female, Humans, Remission Induction, Time Factors, Vagina, Fluconazole, Logistic Models, Drug Resistance, Fungal, Candida glabrata, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
